Axa S.A. Maxcyte, Inc. Transaction History
Axa S.A.
- $33.6 Billion
- Q2 2025
A detailed history of Axa S.A. transactions in Maxcyte, Inc. stock. As of the latest transaction made, Axa S.A. holds 2,202,378 shares of MXCT stock, worth $3.33 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,202,378
Previous 986,897
123.16%
Holding current value
$3.33 Million
Previous $2.69 Million
78.21%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding MXCT
# of Institutions
119Shares Held
70.8MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY8.91MShares$13.5 Million1.1% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$12.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY7.03MShares$10.6 Million0.0% of portfolio
-
Mirabella Financial Services LLP London, X06.6MShares$9.97 Million1.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$8.46 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $154M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...